NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.
Fleming Mathew ; Amandeep Goyal .
Last Update: August 11, 2024 .
Ethanol is an alcohol that may be administered clinically to treat methanol and ethylene glycol toxicity and is applied to surfaces for disinfection and sterilization. Ethanol has also emerged as a novel cancer therapy, offering an alternative to surgical interventions. The activity discusses the indications, mechanism of action, administration, adverse effects, and contraindications for ethanol administration. Understanding ethanol's pharmacology enables healthcare professionals to optimize dosing and minimize adverse reactions. Emphasis is placed on the crucial role of the interprofessional healthcare team in managing ethanol therapy. This discussion equips healthcare professionals with the knowledge required to safely and effectively administer ethanol, improving patient outcomes and care standards.
Identify the therapeutic indications for ethanol administration.Evaluate the mechanisms contributing to ethanol's clinical efficacy across various clinical applications.
Determine the appropriate management of ethanol toxicity.Implement effective collaboration and communication among interprofessional team members to ensure appropriate candidate selection for percutaneous ethanol ablation versus surgery, thereby minimizing surgery-related comorbidities and optimizing patient outcomes.
Ethanol is formed during the fermentation of naturally occurring sugars. This chemical's structure consists of a pair of carbon atoms with an alkyl group coupled with an -OH functional group; this -OH group makes the molecule an alcohol, denoted by the "-ol" suffix. Unlike other alcohols (eg, methanol, butanol, propanol), humans can consume ethanol in its purest form without dying.
Indications
Clinicians may already be aware of the common clinical uses for ethanol, including as a hand sanitizer to prevent healthcare-associated infections (HCAIs) and as part of lock therapy to reduce the incidence of IV catheter-related bloodstream infections (CRBIs).[1][2] The administration of ethanol to prevent toxic metabolite formation may also be apparent. However, recent evidence suggests ethanol's potential as a novel therapy for the scenarios below.
Fomepizole alternative:
Fomepizole is FDA-approved to treat patients with methanol or ethylene glycol poisoning, and it has a far greater affinity for ADH than ethanol. Even though fomepizole is a superior antidote, its limited availability and a general lack of knowledge among clinicians regarding fomepizole's pharmaceutical features have led to the continued use of ethanol infusions as a treatment for these patients.[3][4]
Ethanol may be administered as an alternative to fomepizole for patients with:
Methanol poisoning: Patients with ≥20 mg/dL plasma methanol should start therapy immediately [5] Ethylene glycol poisoning [6]Commerical preparation of ethanol is no longer available in the USA; reconstitution is required.
Ablative, embolic, or sclerosing agent:
Recent studies have shown that ethanol may be used in specific scenarios listed below.[7]
As an ablative agent for patients with:
Hypertrophic obstructive cardiomyopathy [8] Thyroid cystic nodules [9] Single insulinoma (endoscopic ultrasound-guided) [10] Hepatocellular carcinomas [11] Cancer-associated brachial plexus pain [12] Cancer-associated upper abdominal/splanchnic nerve pain [13]As an embolic agent for patients with: Arteriovenous malformations [14]
As a sclerosing agent:
Surgical alternative [15] Reduce mortality associated with tumor resections [15] Painful musculoskeletal hemangiomas [10] Painful trigeminal neuralgia [16] Lymphatic malformations in the neck and mediastinum (CT-guided) [17] Symptomatic, simple renal cysts [18]Methanol poisoning: Methanol is less toxic than its metabolized counterpart, formic acid. Alcohol dehydrogenase (ADH) converts methanol into formaldehyde. Aldehyde dehydrogenase (ADLH) converts formaldehyde into formic acid, a chemical responsible for the harmful effects associated with methanol poisoning, such as vision loss and Parkinsonian movements. This process is the same for ethanol. However, ethanol has a greater affinity for ADH and ADLH than methanol; ethanol administration competitively inhibits methanol metabolism, reducing the formation of formic acid.
Ethylene glycol poisoning: Similar to methanol, ethylene glycol is metabolized by ADH in the liver to form glycolaldehyde, which ALDH converts to glycolic acid. Glycolic acid may be further metabolized into oxalic acid. Glycolic acid is more toxic than ethylene glycol, and oxalic acid can form calcium oxalate crystals in the kidney. Ethanol also has a greater affinity for ADH and ADLH than ethylene glycol and competitively inhibits ethylene glycol metabolism.
Hand Sanitizer and Sepsis Prevention
Many surveys have reported the global burden of healthcare-associated infections (HCAIs). Alcohols exhibit antimicrobial activity by denaturing and coagulating proteins within the microbial cell wall. Ethanol is also effective against viruses and can be combined with other alcohols to achieve a powerful synergistic effect against various microorganisms.
Ethanol lock therapy (ELT): This therapy primarily benefits patients receiving total parenteral nutrition. An ethanol lock created in the lumen of the IV catheter kills and prevents the growth of bacteria, significantly reducing catheter-related bloodstream infections (CRBSIs). No reports of bacteria exhibiting resistance to ethanol have been documented.
Ablative/Sclerosing/Embolic Agent
Ethanol may be used to treat various neoplasms, cysts, and vascular malformations or induce neurolysis. Ethanol is directly toxic and dehydrating to cells that form the endothelial lining, causing fibrotic changes. This fibrosis leads to ischemia and size reduction of tumors and other hyperplastic growths.[19]
Available Dosage Forms and Strengths
Ethanol solution is clinically available as a 95% solution in 1.0 mL and 5.0 mL vials for injection and as a 70% solution for use during ethanol lock therapy. Ethanol is also commercially available as a 10% solution. Intravenous infusion is the preferred method for patients with methanol or ethylene glycol poisoning. However, ethanol may also be administered orally or through a nasogastric tube.
Adult Dosing
Hand sanitizer:
Alcohol-based hand sanitizer (ABHS) is known to prevent nosocomial infections. However, the efficacy of these compounds against neutralizing microorganisms is dependent mainly on the effectiveness of their use. Several studies recommend applying 2.4 to 3 mL for a minimum of 30 seconds to ensure maximum possible disinfection.[1]
Methanol toxicity:
The loading and maintenance doses should be carefully monitored in an intensive care setting to prevent any toxic effect of ethanol itself.
Ethanol solution (95%):
Loading dose (oral or NG tube): 600-700 mg/kg, diluted to ≤20% with water or juiceEthanol solution (10%):
The dose is reduced for patients with a positive blood ethanol level 0.83 mL/kg/hr (65-155 mg/kg/hr) for healthy patients. Patients with chronic alcohol use disorder or who are on hemodialysis require higher doses. 1.5 mL/kg/hr until a plasma ethanol level of 100 mg/dL is achieved.Patient ethanol levels are obtained hourly until this threshold. Afterward, ethanol levels may be obtained every 2-4 hours.
Ethanol lock therapy:
Ethanol lock therapy (ELT) and regular antibiotic therapy may be co-administered over 4-6 hours. This regimen significantly reduces the incidence of catheter-related bloodstream infections (CRBSI).
Ablation or sclerosis:
Ethanol is injected directly into the lesion or parenchyma of the specific organ or tissue. Clinicians may be guided by endoscopic ultrasound or CT.
Pediatric Dosing
Methanol toxicity:
Ethanol solution (95%):
Loading dose (oral): 0.8-1.0 mL/kg Maintenance (oral): 0.1 mL/kg/hEthanol solution (10% = 7.9 g/dL):
Loading dose (IV): 8-10 mL/kg, not to exceed 200 mL total Maintenance (IV): 0.83 mL/kg/hDuring the liver's conversion of ethanol to acetaldehyde, the electron carrier NAD + donates 2 electrons to this reaction. In the process, NAD + is reduced to NADH, increasing the NADH/NAD + ratio in the hepatocytes.
An elevated NADH/NAD + ratio causes:
Ketoacidosis: The citric acid (TCA) cycle inhibition increases acetyl-CoA levels. This excess acetyl-CoA is shunted into the ketogenesis pathway, resulting in increased production of ketoacids (eg, acetoacetic acid).
Fasting hypoglycemia: The increased NADH/NAD + ratio inhibits the conversion of malate to oxaloacetate (OAA). The resulting reaction equilibrium forces OAA to be converted back into malate. Oxaloacetate may also be converted into phosphoenolpyruvate (PEP). By inhibiting the formation of OAA, an elevated NADH/NAD + ratio impairs gluconeogenesis.
Hepatic steatosis: An increased NADH/NAD + ratio stimulates fatty acid and glycerol-3-phosphate synthesis. These combine to increase TAG levels, resulting in fatty liver.
Ingested ethanol is primarily metabolized in the liver; hepatic damage often accompanies chronic alcohol consumption. This damage can lead to steatosis, cirrhosis, and hepatic carcinoma. Other affected organs/organ systems include:
Gastrointestinal: Gastritis, malabsorption, carcinoma Cardiovascular: Hypertension, cardiomyopathy, arrhythmia Renal: Glomerulonephritis, AKI Reproductive: Infertility, premature birth, low birth weight, fetal alcohol syndrome Pancreas: Pancreatitis Breast: Carcinoma Neurological/psychiatric: Stroke, depression, meningitis, cerebellar degeneration [20]Ethanol must not be administered concurrently with fomepizole, which inhibits ethanol metabolism and prolongs its half-life. This inhibition can result in significantly elevated ethanol levels and possible manifestations of ethanol intoxication. Contraindications to ethanol administration also include pregnancy and breastfeeding.
Hand Sanitizer
Although there is no objective contraindication for alcohol-based hand sanitizer (ABHS) in any particular medical setting, it is common knowledge that ABHS doesn't kill all harmful microorganisms, including the spores of Clostridium difficile. ABHS is also ineffective against some protozoan oocysts (eg, Cryptosporidium) and non-enveloped viruses (eg, norovirus). Handwashing using soap and water is more effective against these organisms than ABHS.[1]
Percutaneous ethanol injection as part of ablation therapy is contraindicated when:
Prothrombin time (PT) is less than 40% of normal Platelet count <40,000/mm 3 [21]Ethanol demonstrates zero-order kinetics. Alcohol is primarily absorbed in the proximal small intestine, but a small fraction is also absorbed by the mucosal layer of the mouth, esophagus, and stomach. Alcohol is primarily metabolized in the liver; the rate of oxidation per unit time yields a linear curve. Insulin release stimulates ethanol metabolism, while conditions like starvation impair this process. Alcohol metabolism occurs via an oxidative and non-oxidative pathway. Various enzymes play a role in the oxidative pathway, including alcohol dehydrogenase (ADH) in the cytosol, aldehyde dehydrogenase (ALDH) in mitochondria, cytochrome P450 (CYP2E1) in microsomes, and catalase in peroxisomes. The non-oxidative pathway includes the enzymes fatty acid ethyl ester synthase (FAEES) and phospholipase D (PLD). The administration of medications that inhibit the oxidative pathway enzymes drive non-oxidative metabolism.[22]
In the oxidative pathway, ethanol is first converted to acetaldehyde by alcohol dehydrogenase (ADH) in the cytosol of hepatocytes. NAD + serves as an electron carrier for this reaction and is reduced to NADH. This process significantly reduces the cytosol, predisposing to damage by reactive oxygen species (ROS) and other byproducts of alcohol metabolism. The drug fomepizole competitively inhibits ADH, preventing the formation of toxic metabolites.
Acetaldehyde is further oxidized in the liver by acetaldehyde dehydrogenase (ALDH) to acetic acid, which is converted to acetyl-CoA by acetyl-CoA synthetase. Acetyl-CoA is eventually transformed into acetone through ketoacid intermediates. Acetone is oxidized to CO2 in the cardiac and skeletal muscles and the brain. Administration of disulfiram (an acetaldehyde dehydrogenase inhibitor) delays acetaldehyde clearance, causing symptoms such as nausea, vomiting, chest and abdominal pain, dizziness, and worsening hangover. This medication may be used to help treat alcohol use disorders. Drugs that exhibit properties similar to disulfiram include metronidazole, sulfamethoxazole and trimethoprim, chloramphenicol, quinacrine, first-generation sulfonylureas, griseofulvin, and some cephalosporins such as cefotetan and cefoperazone.
The non-oxidative pathway produces fatty acid ethyl esters (FAEEs), which cause tissue damage and form phosphatidyl ethanol from phospholipase D. Given phospholipase D's role in cell signaling, excessive non-oxidative pathway activation can impair this communication.[22] Transient heart block can occur after alcohol septal ablation procedures, necessitating the insertion of a temporary pacemaker.[23] About 10% of these heart blocks persist and require a permanent pacemaker.
Alcohol intoxication causes CNS depression by enhancing the inhibitory effect of GABA on its receptors. Alcohol also inhibits the effects of glutamate on NMDA receptors, resulting in disinhibition and a blunted mental state. Ethanol intoxication manifests as slurred speech, stupor, and gait abnormalities. Severe intoxication may even result in a coma.
Clinicians should first correct thiamine (vitamin B1) deficiency, which often accompanies chronic alcohol use disorder. Electrolyte derangements should be corrected through appropriate infusion. Extensive counseling is frequently required for patients with alcohol use disorder. Some medications that promote alcohol cessation include naltrexone (μ-opioid receptor antagonist), disulfiram (negative conditioning), topiramate, and gabapentin.
Alcohol withdrawal is another common morbidity that arises as a complication of alcohol use disorder (AUD). Alcohol withdrawal syndrome (AWS) occurs due to abrupt cessation of alcohol consumption after binge drinking or long-term dependence. The signs and symptoms range from mild (eg, anxiety, headache, palpitations) to severe (eg, seizures, delirium tremens). The features of AWS typically arise within 24 hours of discontinuing alcohol consumption. Treatment involves supportive therapy for complaints. Any associated comorbidities should be treated with a 'banana bag' of essential vitamins. Severe AWS is an indication for benzodiazepine administration.[24]
Ethanol has existed as a recreational beverage since the beginning of civilization. Over the past century, extensive research has demonstrated ethanol's uses for treating disease. Ethanol has become indispensable in preventing hospital-acquired infections as a component of hand sanitizer formulas. Healthcare providers (including clinicians, mid-level providers, nurses, and pharmacists) must sanitize their hands and wear gloves before touching the patient or handling equipment (eg, catheter tubes, cannulas). This principle is also the basis of ethanol lock therapy in an ICU setting to prevent sepsis associated with infected catheters.
Ethanol is currently being studied as an ablative agent for treating different neoplastic conditions that cannot be treated with surgery. The surgeon must evaluate appropriate candidates based on age, financial status, and comorbid conditions to appropriately recommend ethanol ablation over classic surgery for the purpose of preventing mortality.
Ethanol has been used for decades as a treatment for methanol or ethylene glycol poisoning. Even though fomepizole has emerged as a better antidote due to its superior neutralization of the offending agent, more predictable pharmacokinetics, and lower associated mortality, many still prefer ethanol due to its low cost and greater physician familiarity.
Alcohol use disorder remains a global challenge, considering the mortality that correlates with misuse. More than 135 million Americans aged 12 and older actively use alcohol.[25] The clinician must identify and counsel these patients. If necessary, they should be hospitalized and receive appropriate treatment. The optimal therapeutic use of ethanol may be achieved through an interprofessional healthcare team, including clinicians (MDs, DOs, NPs, PAs), nursing staff, and pharmacists, who work collaboratively to achieve optimal patient outcomes with minimal adverse events.
Gold NA, Mirza TM, Avva U. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 9, 2023. Alcohol Sanitizer. [PubMed : 30020626 ]
Opilla MT, Kirby DF, Edmond MB. Use of ethanol lock therapy to reduce the incidence of catheter-related bloodstream infections in home parenteral nutrition patients. JPEN J Parenter Enteral Nutr. 2007 Jul-Aug; 31 (4):302-5. [PubMed : 17595439 ]
Ekins BR, Rollins DE, Duffy DP, Gregory MC. Standardized treatment of severe methanol poisoning with ethanol and hemodialysis. West J Med. 1985 Mar; 142 (3):337-40. [PMC free article : PMC1306022 ] [PubMed : 3993008 ]
Hantson P, Wittebole X, Haufroid V. Ethanol therapy for methanol poisoning: duration and problems. Eur J Emerg Med. 2002 Sep; 9 (3):278-9. [PubMed : 12394629 ]
Ashurst JV, Nappe TM. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jun 12, 2023. Methanol Toxicity. [PubMed : 29489213 ]
Brent J. Current management of ethylene glycol poisoning. Drugs. 2001; 61 (7):979-88. [PubMed : 11434452 ]
Le Daré B, Gicquel T. Therapeutic Applications of Ethanol: A Review. J Pharm Pharm Sci. 2019; 22 (1):525-535. [PubMed : 31604058 ]
Alam M, Dokainish H, Lakkis NM. Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs. myectomy: a meta-analysis. Eur Heart J. 2009 May; 30 (9):1080-7. [PubMed : 19233857 ]
Hahn SY, Shin JH, Na DG, Ha EJ, Ahn HS, Lim HK, Lee JH, Park JS, Kim JH, Sung JY, Lee JH, Baek JH, Yoon JH, Sim JS, Lee KH, Baek SM, Jung SL, Kim YK, Choi YJ., Korean Society of Thyroid Radiology (KSThR). Korean Society of Radiology. Ethanol Ablation of the Thyroid Nodules: 2018 Consensus Statement by the Korean Society of Thyroid Radiology. Korean J Radiol. 2019 Apr; 20 (4):609-620. [PMC free article : PMC6424836 ] [PubMed : 30887743 ]
Qin SY, Lu XP, Jiang HX. EUS-guided ethanol ablation of insulinomas: case series and literature review. Medicine (Baltimore). 2014 Sep; 93 (14):e85. [PMC free article : PMC4616284 ] [PubMed : 25255024 ]
Livraghi T, Benedini V, Lazzaroni S, Meloni F, Torzilli G, Vettori C. Long term results of single session percutaneous ethanol injection in patients with large hepatocellular carcinoma. Cancer. 1998 Jul 01; 83 (1):48-57. [PubMed : 9655292 ]
Loh TH, Patel S, Mirchandani A, Eckmann M. Brachial Plexus Chemical Neurolysis with Ethanol for Cancer Pain. Case Rep Med. 2018; 2018 :8628645. [PMC free article : PMC6081596 ] [PubMed : 30140288 ]
Fujita Y. CT-guided neurolytic splanchnic nerve block with alcohol. Pain. 1993 Dec; 55 (3):363-366. [PubMed : 8121698 ]
Yakes WF, Luethke JM, Parker SH, Stavros AT, Rak KM, Hopper KD, Dreisbach JN, Griffin DJ, Seibert CE, Carter TE. Ethanol embolization of vascular malformations. Radiographics. 1990 Sep; 10 (5):787-96. [PubMed : 2217971 ]
Crawford EA, Slotcavage RL, King JJ, Lackman RD, Ogilvie CM. Ethanol sclerotherapy reduces pain in symptomatic musculoskeletal hemangiomas. Clin Orthop Relat Res. 2009 Nov; 467 (11):2955-61. [PMC free article : PMC2758985 ] [PubMed : 19536604 ]
McLeod NM, Patton DW. Peripheral alcohol injections in the management of trigeminal neuralgia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jul; 104 (1):12-7. [PubMed : 17428701 ]
Impellizzeri P, Romeo C, Borruto FA, Granata F, Scalfari G, De Ponte FS, Longo M. Sclerotherapy for cervical cystic lymphatic malformations in children. Our experience with computed tomography-guided 98% sterile ethanol insertion and a review of the literature. J Pediatr Surg. 2010 Dec; 45 (12):2473-8. [PubMed : 21129570 ]
Hanna RM, Dahniya MH. Aspiration and sclerotherapy of symptomatic simple renal cysts: value of two injections of a sclerosing agent. AJR Am J Roentgenol. 1996 Sep; 167 (3):781-3. [PubMed : 8751700 ]
Burton KR, O'Dwyer H, Scudamore C. Percutaneous ethanol ablation of hepatocellular carcinoma: periprocedural onset alcohol toxicity and pancreatitis following conventional percutaneous ethanol ablation treatment. Can J Gastroenterol. 2009 Aug; 23 (8):554-6. [PMC free article : PMC2732177 ] [PubMed : 19668800 ]
Rusyn I, Bataller R. Alcohol and toxicity. J Hepatol. 2013 Aug; 59 (2):387-8. [PMC free article : PMC3959903 ] [PubMed : 23391479 ]
Di Stasi M, Buscarini L, Livraghi T, Giorgio A, Salmi A, De Sio I, Brunello F, Solmi L, Caturelli E, Magnolfi F, Caremani M, Filice C. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma. A multicenter survey of evaluation practices and complication rates. Scand J Gastroenterol. 1997 Nov; 32 (11):1168-73. [PubMed : 9399400 ]
Zakhari S. Overview: how is alcohol metabolized by the body? Alcohol Res Health. 2006; 29 (4):245-54. [PMC free article : PMC6527027 ] [PubMed : 17718403 ]
El-Sabawi B, Nishimura RA, Cha YM, Bradley DJ, Klarich KW, Rihal CS, Eleid MF. Transient Complete Heart Block After Alcohol Septal Ablation: Incidence of Recurrence and Need for Permanent Pacemaker. Circ Cardiovasc Interv. 2020 Aug; 13 (8):e009202. [PubMed : 32757660 ]
Canver BR, Newman RK, Gomez AE. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Feb 14, 2024. Alcohol Withdrawal Syndrome. [PubMed : 28722912 ]
Nehring SM, Chen RJ, Freeman AM. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Mar 16, 2024. Alcohol Use Disorder. [PubMed : 28613774 ]
Disclosure: Fleming Mathew declares no relevant financial relationships with ineligible companies.
Disclosure: Amandeep Goyal declares no relevant financial relationships with ineligible companies.
